Literature DB >> 6842340

Trial of low doses of aspirin as prophylaxis in sickle cell disease.

J Greenberg, K Ohene-Frempong, J Halus, C Way, E Schwartz.   

Abstract

The effects of low doses of aspirin on the frequency and severity of painful vaso-occlusive crises were evaluated in children with sickle hemoglobinopathies. Aspirin was compared with placebo in 49 patients in a double-blind crossover study. Careful monitoring of patients revealed an average of 1.1 painful crises per patient year. During the 21 months of study, 70% of patients had a maximum of two painful crises, and 25% experienced four or more. The frequency and severity of crises were not affected by aspirin therapy. In view of aspirin's demonstrated effect on platelet function, we suggest that platelets do not contribute to the initiation or progression of the vaso-occlusive process.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6842340     DOI: 10.1016/s0022-3476(83)80258-3

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  17 in total

1.  P-selectin-mediated platelet-neutrophil aggregate formation activates neutrophils in mouse and human sickle cell disease.

Authors:  Renata Polanowska-Grabowska; Kori Wallace; Joshua J Field; Lanlin Chen; Melissa A Marshall; Robert Figler; Adrian R L Gear; Joel Linden
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-11-11       Impact factor: 8.311

2.  Health status in sickle cell disease: examining the roles of pain coping strategies, somatic awareness, and negative affectivity.

Authors:  J D McCrae; M A Lumley
Journal:  J Behav Med       Date:  1998-02

Review 3.  Treating sickle cell disease by targeting HbS polymerization.

Authors:  William A Eaton; H Franklin Bunn
Journal:  Blood       Date:  2017-04-06       Impact factor: 22.113

Review 4.  Pharmacotherapeutical strategies in the prevention of acute, vaso-occlusive pain in sickle cell disease: a systematic review.

Authors:  Joep W R Sins; David J Mager; Shyrin C A T Davis; Bart J Biemond; Karin Fijnvandraat
Journal:  Blood Adv       Date:  2017-08-22

5.  Role of the coagulation system in the pathogenesis of sickle cell disease.

Authors:  Md Nasimuzzaman; Punam Malik
Journal:  Blood Adv       Date:  2019-10-22

Review 6.  Role of the hemostatic system on sickle cell disease pathophysiology and potential therapeutics.

Authors:  Zahra Pakbaz; Ted Wun
Journal:  Hematol Oncol Clin North Am       Date:  2014-01-18       Impact factor: 3.722

7.  Genetic diminution of circulating prothrombin ameliorates multiorgan pathologies in sickle cell disease mice.

Authors:  Paritha I Arumugam; Eric S Mullins; Shiva Kumar Shanmukhappa; Brett P Monia; Anastacia Loberg; Maureen A Shaw; Tilat Rizvi; Janaka Wansapura; Jay L Degen; Punam Malik
Journal:  Blood       Date:  2015-08-18       Impact factor: 22.113

Review 8.  Interplay between coagulation and vascular inflammation in sickle cell disease.

Authors:  Erica Sparkenbaugh; Rafal Pawlinski
Journal:  Br J Haematol       Date:  2013-04-18       Impact factor: 6.998

Review 9.  Coagulation abnormalities of sickle cell disease: Relationship with clinical outcomes and the effect of disease modifying therapies.

Authors:  Denis Noubouossie; Nigel S Key; Kenneth I Ataga
Journal:  Blood Rev       Date:  2015-12-24       Impact factor: 8.250

10.  Morphological and functional platelet abnormalities in Berkeley sickle cell mice.

Authors:  Arun S Shet; Thomas J Hoffmann; Marketa Jirouskova; Christin A Janczak; Jacqueline R M Stevens; Adewole Adamson; Narla Mohandas; Elizabeth A Manci; Therese Cynober; Barry S Coller
Journal:  Blood Cells Mol Dis       Date:  2008-04-18       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.